InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $2.050 0.01 (0.49%)+

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,662 Successful Repair/Regeneration Damaged Intervertebral Discs 10 Sep 2009 11:58AM $1.095 $2.050 risen by 87.21%
$2,662 Preliminary Final Report 26 Aug 2009 11:59AM n/a $2.050 n/a
$2,662 USA Associate Company Closes $10M Equity-Based Financing 25 Aug 2009 10:35AM $1.060 $2.050 risen by 93.40%
$2,662 Associate Company Angioblast Systems Raises New Capital 19 Aug 2009 10:35AM $1.160 $2.050 risen by 76.72%
$2,662 Trading Halt 17 Aug 2009 1:26PM $1.190 $2.050 risen by 72.27%
$2,662 FDA Clears Trial in Minimally Invasive Lumbar Spinal Fusion 17 Aug 2009 10:07AM $1.190 $2.050 risen by 72.27%
$2,662 USA Trial to use Patented Cells with Heart Assist Devices 5 Aug 2009 8:54AM $1.185 $2.050 risen by 73%
$2,662 Appendix 4C - quarterly 30 Jul 2009 9:17AM $1.140 $2.050 risen by 79.82%
$2,662 MSB to Apply for Regulatory Approval of Bone Repair Products 23 Jul 2009 9:30AM $1.000 $2.050 risen by 105%
$2,662 Patients in Bone Marrow Trial Show Earlier Engraftment 24 Jun 2009 10:20AM $0.770 $2.050 risen by 166.23%
$2,662 Results Show Significant Heart Function Improvement 14 May 2009 9:09AM $0.770 $2.050 risen by 166.23%
$2,662 Appendix 4C - quarterly 1 May 2009 9:30AM $0.780 $2.050 risen by 162.82%
$2,662 MSB Commences Clinical Program for Fusion of Cervical Spine 28 Apr 2009 10:22AM $0.790 $2.050 risen by 159.49%
$2,662 Mesoblast Raises Capital for New Clinical Programs 30 Mar 2009 10:43AM $0.800 $2.050 risen by 156.25%
$2,662 Trading Halt 26 Mar 2009 9:53AM $0.800 $2.050 risen by 156.25%
$2,662 Half Yearly Report and Accounts 26 Feb 2009 10:34AM $0.790 $2.050 risen by 159.49%
$2,662 Heart Failure Patients Pass Key Safety Milestone 25 Feb 2009 8:48AM $0.800 $2.050 risen by 156.25%
$2,662 ParkwayHealth Collaboration to use Mesoblast Cells 16 Feb 2009 9:59AM $0.805 $2.050 risen by 154.66%
$2,662 Appendix 4C - quarterly 30 Jan 2009 3:03PM $0.780 $2.050 risen by 162.82%
$2,662 Stem Cells Approved for World First Osteoarthritis Trial 20 Jan 2009 9:09AM $0.860 $2.050 risen by 138.37%
$2,662 Investor Briefing - The CEO Transcript 24 Nov 2008 9:45AM $0.850 $2.050 risen by 141.18%
$2,662 Major USA Cardiology Conference Highlights Proprietary Cells 11 Nov 2008 9:25AM $1.000 $2.050 risen by 105%
$2,662 FDA Clears Bone Marrow Transplant Trial Using Patented Cells 5 Nov 2008 10:35AM $1.050 $2.050 risen by 95.24%
$2,662 Appendix 4C - quarterly 31 Oct 2008 12:18PM $1.050 $2.050 risen by 95.24%
$2,662 First Heart Failure Patients Implanted with Stem Cells in US 13 Oct 2008 9:20AM $0.995 $2.050 risen by 106.03%

1076 - 1100 of 1175 results

Page 44 of 47

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.